Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
Antineoplastic Combined Chemotherapy Protocols
Docetaxel and (153)Sm-EDTMP can be combined safely at full doses over repeated cycles. Responses were seen in the small group of patients with taxane-resistant disease tested. The optimal phase II doses for patients with taxane-naïve disease may differ from those optimal for patients with taxane-resistant disease.